Biochip emerges from combination of microfabrication technology and biology technology. It integrates many discontinuous processes of life sciences such as sample preparation, chemical reaction and detection into the ...Biochip emerges from combination of microfabrication technology and biology technology. It integrates many discontinuous processes of life sciences such as sample preparation, chemical reaction and detection into the microchip and makes it become continuous and subminiature. Lab-on-a-chip, biochemistry analysis system based on biochip technology, has the features of small size, low cost, high automation, high analysis speed, high-information, contamination-proof little sample and reagent consumption, etc. It will be applied in the areas of biology, medical science, life science etc. in the near future. In this paper, the applications of biochip in the field of basic life science research and its recent development are reviewed.展开更多
As a new technology, biochip has enjoyed its rapid development for its high-speed and parallel feature. Lab-on-a-chip, based on the biochip technology, integrates the non-continuous process of the life sciences into a...As a new technology, biochip has enjoyed its rapid development for its high-speed and parallel feature. Lab-on-a-chip, based on the biochip technology, integrates the non-continuous process of the life sciences into a microchip. Biochip technology is believed to revolutionize the future research in life sciences, disease diagnosis, forensic sciences and outer space exploitation. We focus on the applications of biochip in the medicine area, such as disease diagnosis, and study of disease mechanism.展开更多
文摘Biochip emerges from combination of microfabrication technology and biology technology. It integrates many discontinuous processes of life sciences such as sample preparation, chemical reaction and detection into the microchip and makes it become continuous and subminiature. Lab-on-a-chip, biochemistry analysis system based on biochip technology, has the features of small size, low cost, high automation, high analysis speed, high-information, contamination-proof little sample and reagent consumption, etc. It will be applied in the areas of biology, medical science, life science etc. in the near future. In this paper, the applications of biochip in the field of basic life science research and its recent development are reviewed.
文摘As a new technology, biochip has enjoyed its rapid development for its high-speed and parallel feature. Lab-on-a-chip, based on the biochip technology, integrates the non-continuous process of the life sciences into a microchip. Biochip technology is believed to revolutionize the future research in life sciences, disease diagnosis, forensic sciences and outer space exploitation. We focus on the applications of biochip in the medicine area, such as disease diagnosis, and study of disease mechanism.
文摘目的确诊前列腺癌患者行去势治疗后易进展为去势抵抗性前列腺癌(castration-resistant prostate cancer,CRPC),现临床仍缺乏可预判进展为CRPC的可靠指标。本研究旨在从临床病例中获取信息,探讨前列腺癌患者Gleason评分与首发总前列腺癌特异性抗原(total prostate cancer specific antigen,TPSA)、预后、骨转移及前列腺癌内分泌治疗患者进展为CRPC之间的关系。方法收集中国医科大学附属盛京医院2012-01-01-2013-12-31收治的88例病理确诊为前列腺癌的病例资料,随访时间截止到2017-06-03。将患者按2005年Gleason评分系统分成2组(中低危组≤7分和高危组>7分)。采用Spearman等级相关分析、χ~2检验、Kaplan-Meier生存分析和Log-rank检验等统计方法,分别讨论2组预后、CRPC无进展中位时间以及Gleason评分的高低是否对预测骨转移有影响。结果 88例患者中Gleason评分与TPSA正相关,r=0.595,P<0.01。中低危组56例,出现骨转移14例;高危组32例,出现骨转移18例,组间骨转移概率差异有统计学意义,χ~2=8.594,P=0.003。2组总样本数/死亡事件发生例数分别为56/12和32/18,高危组中位总生存时间(overall survival,OS)的95%CI为49.0个月(38.9~59.0个月);中低危组中位OS还需随访,2组患者生存时间差异有统计学意义,χ~2=12.25,P=0.01。就治疗方式而言,根治术或根治术联合去势治疗、抗雄治疗的患者,均未出现因前列腺癌死亡;使用去势治疗联合抗雄治疗的患者63例中就有17例因前列腺癌死亡。内分泌治疗的患者中,中低危组39例,高危组24例,出现CRPC进展分别为18、17例。中低危组无进展的中位时间为60.00个月(46.47~73.52个月),高危组为36.00个月(16.97~55.02个月),差异有统计学意义,χ~2=7.223,P=0.007。结论 Gleason评分与首发总TPSA存在正相关关系;评分越高患者的骨转移概率相应增加,生存时间减少,CRPC进展时间更短。
